ArticleBlood advances2022
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 74 citations in OpenAlex.
- Donor selection for allogeneic hematopoietic cell transplantation in the posttransplant cyclophosphamide era.International journal of hematology · 2026Review
- Inotuzumab Ozogamicin in Clinical Practice: an Overview of Efficacy, Safety, and Real-World Applications.Current hematologic malignancy reports · 2026Review
- Advances and Controversies in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Navigating First-Line Therapies.Current hematologic malignancy reports · 2026Review
- A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia.British journal of haematology · 2026Review
- Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study.Therapeutic advances in hematology · 2026Article
- Allogeneic Stem Cell Transplantation in Patients With Mixed Chimerism Following Double Cord Blood Transplantation: A Case Report.Case reports in hematology · 2026Article
- Haploidentical versus matched unrelated donor hematopoietic cell transplantation for adult patients with refractory/relapsed acute lymphoblastic leukemia: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Bone marrow transplantation · 2025Article
- Article
- The Cox Model With Adaptive Fused Group Bridge Penalty to Incorporate Historical Data Into the Analysis of Clinical Trials With an Application to BMT CTN 1101.Statistics in medicine · 2025Article
- Impact of haplo-donor age on transplant outcomes: a comparative analysis of haploidentical vs cord blood transplantation.Blood advances · 2025Article
- The Role of Transplant for Philadelphia-positive B-cell Acute Lymphoblastic Leukemia in 2025.Current oncology reports · 2025Review
- Risk factors for positive post-transplantation measurable residual disease in patients with acute lymphoblastic leukemia.Chinese medical journal · 2025Article
- Indirect presentation of mismatched human leukocyte antigen-B associates with outcomes of cord blood transplantation.British journal of haematology · 2025Article
- Review
- Transplant in ALL: who, when, and how?Hematology. American Society of Hematology. Education Program · 2024Review
- Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma.Bone marrow transplantation · 2024Article
- Superior survival with allogeneic hematopoietic stem cell transplantationHaematologica · 2024Article
- Article
- Preliminary Data on SNP of Transplantation-Related Genes after Haploidentical Stem Cell Transplantation.Journal of clinical medicine · 2024Article
- Outcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients and Donors.Transplantation and cellular therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
77 authors at 20 institutions in 12 countries.
Matthew J WieduwiltUniversity of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK.
Leland MethenyUniversity Hospitals Seidman Cancer Center, Cleveland, OH.
Mei-Jie ZhangCenter for International Blood and Marrow Transplant Research, Department of Medicine, and.
Hai-Lin WangCenter for International Blood and Marrow Transplant Research, Department of Medicine, and.
Noel Estrada-MerlyCenter for International Blood and Marrow Transplant Research, Department of Medicine, and.
David I MarksAdult Bone Marrow Transplant, University Hospitals Bristol National Health Service Trust, Bristol, UK.
A Samer Al-HomsiNew York University Langone Health, New York, NY.
Lori MufflyDivision of Blood and Marrow Transplantation, Stanford University, Stanford, CA.ORCID 0000-0002-9887-6136
Nelson ChaoDivision of Cell Therapy and Hematology, Department of Medicine, Duke University Medical Center, Durham, NC.ORCID 0000-0001-6725-7220
David RizzieriDivision of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC.ORCID 0000-0001-9886-5771
Robert Peter GaleHaematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK.
Shahinaz M GadallaDivision of Cancer Epidemiology and Genetics, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Rockville, MD.ORCID 0000-0002-3255-8143
Mitchell CairoDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY.
Alberto MussettiHematology Department, Institut Catalá d'Oncologia-Hospitalet, Barcelona, Spain.
Steven GoreYale New Haven Hospital, New Haven, CT.
Vijaya Raj BhattThe Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0003-2513-0533
Sagar S PatelBlood and Marrow Transplant Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.ORCID 0000-0001-9949-3615
Fotios V MichelisAllogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada.ORCID 0000-0003-2956-0848
Yoshihiro InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Sherif M BadawyDivision of Hematology, Oncology and Stem Cell Transplant, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
Edward CopelanDeparment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Neil PalmisianoSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA.
Mohamed A Kharfan-DabajaDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL.ORCID 0000-0001-7394-5185
Hillard M LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH.
Siddhartha GangulyDivision of Hematological Malignancies and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS.
Christopher BredesonThe Ottawa Hospital Transplant and Cellular Therapy Program, Ottawa, ON, Canada.
Miguel Angel Diaz PerezDepartment of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain.
Ryan CassadayFred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.
Bipin N SavaniDivision of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.ORCID 0000-0002-3304-9965
Karen BallenDivision of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA.
Rodrigo MartinoDivision of Clinical Hematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.ORCID 0000-0001-5143-4042
Baldeep WirkBone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA.
Ulrike BacherDepartment of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0001-8771-947X
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia.
Asad BasheyBlood and Marrow Transplant Program at Northside Hospital, Atlanta, GA.
Hemant S MurthyDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL.
Jean A YaredBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD.
Ibrahim AldossCity of Hope Medical Center, Duarte, CA.
Nosha FarhadfarDivision of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL.
Hongtao LiuSection of Hematology/Oncology, University of Chicago Medicine, Chicago, IL.ORCID 0000-0002-3190-7807
Hisham Abdel-AzimDivision of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA.
Edmund K WallerDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA.ORCID 0000-0003-0816-6729
Melhem SolhThe Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA.
Matthew D SeftelDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Marjolein van der PoelMaastricht University Medical Center, Maastricht, The Netherlands.
Michael R GrunwaldDeparment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Jane L LiesveldDepartment of Medicine, University of Rochester Medical Center, Rochester, NY.
Rammurti T KambleDivision of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX.
Joseph McGuirkDivision of Hematological Malignancies and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS.ORCID 0000-0002-0539-4796
Reinhold MunkerMarkey Cancer Center, University of Kentucky, Lexington, KY.
Jean-Yves CahnDepartment of Hematology, Centre Hospitalier Universitaire Grenoble Alpes, Université Grenoble Alpes, Grenoble, France.
Jong Wook LeeDivision of Hematology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.
César O FreytesUniversity of Texas Health Science Center at San Antonio, San Antonio, TX.
Maxwell M KremMarkey Cancer Center, University of Kentucky, Lexington, KY.ORCID 0000-0003-3980-480X
Lena E WinestoneDivision of Allergy, Immunology, and Blood and Marrow Transplant, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA.ORCID 0000-0001-9982-1594
Usama GergisDepartment of Medical Oncology, Division of Hematological Malignancies, Thomas Jefferson University, Philadelphia, PA.
Sunita NathanSection of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL.
Richard F OlssonDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-5970-2128
Leo F VerdonckDepartment of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands.
Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-3281-2081
Olle RingdénTranslational Cell Therapy Group, Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-6092-1536
Brian D FriendCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX.ORCID 0000-0001-8652-4400
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, MA.ORCID 0000-0002-6602-5505
Hannah ChoeThe Ohio State University Wexner Medical Center, James Comprehensive Cancer Center, Columbus, OH.
Saurabh ChhabraCenter for International Blood and Marrow Transplant Research, Department of Medicine, and.ORCID 0000-0001-9117-8696
Taiga NishihoriDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.ORCID 0000-0002-2621-7924
Sachiko SeoDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.ORCID 0000-0002-4308-2152
Biju GeorgeChristian Medical College, Vellore, India.ORCID 0000-0002-9847-9501
Lee Ann Baxter-LoweChildren's Hospital Los Angeles, Los Angeles, CA.ORCID 0000-0002-6706-0273
Gerhard C HildebrandtMarkey Cancer Center, University of Kentucky, Lexington, KY.ORCID 0000-0003-0478-3340
Marcos de LimaDepartment of Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH.ORCID 0000-0002-8568-4522
Mark LitzowDivision of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN.ORCID 0000-0002-9816-6302
Partow KebriaeiDepartment of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Christopher S HouriganLaboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.ORCID 0000-0002-6189-8067
Muhammad Bilal AbidDivisions of Hematology/Oncology and Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; and.
Daniel J WeisdorfDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.ORCID 0000-0001-8078-8579
Wael SaberCenter for International Blood and Marrow Transplant Research, Department of Medicine, and.
Medical College of Wisconsin · USUniversity of Kentucky · USBaylor College of Medicine · USLevine Cancer Institute · USMayo Clinic in Florida · USNational Institutes of Health · USNorthside Hospital · USThomas Jefferson University · USUniversity of Kansas · USCentre Hospitalier Universitaire de Grenoble · FRChildren's Hospital of Los Angeles · USChristian Medical College, Vellore · INCity Of Hope National Medical Center · USDokkyo Medical University · JPDuke Medical Center · USDuke University · USEmory University · USHospital de Sant Pau · ESHospital Infantil Universitario Niño Jesús · ESImperial College London · GB
Funding
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNorthwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8MDetection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0MGenetic Modifiers of Cancer RiskZIACP010142 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MIRABELLO, LISA · 2009 to 2025
$17.1MIntegrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5MIntegrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantationR01CA215134 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S, MAJHAIL, NAVNEET S. · 2017 to 2022
$3.6MImproving the Availability of Younger Unrelated Hematopoietic Stem Cell DonorsR01HL130388 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWITZER, GALEN E. · 2016 to 2018
$1.3MNCATS NIH HHS UL1 TR001422NCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA215134NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL130388NIAID NIH HHS R01 AI128775
Abstract
The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.
Indexed as
Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaFetal BloodHumansRetrospective StudiesSiblingsUnrelated Donors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.